Friday 16 May 2025
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • Renewed push to turbo-charge UK-EU science and technology links

Renewed push to turbo-charge UK-EU science and technology links

Pharmaceutical
23 February 2025

New plans have been unveiled to make Britain’s science and technology links with the European Union (EU) stronger and deeper, following a fruitful visit to Brussels by the UK’s Science and Technology Secretary, to meet some of the new slate of European Commissioners.

Today (January 30) the government is announcing the launch of a new nationwide advertising campaign to further boost UK participation in Horizon Europe, the world’s largest program of research collaboration. The UK is also joining four European Research Infrastructure Consortia (ERICs) to further boost collaborative ties between researchers, across the Channel.

The government statement noted that the EU is an innovation powerhouse – spending over 380 billion euros ($39.9 billion) on R&D in 2023 – and fostering deep and high-quality links between the Continent’s brightest minds, and the UK’s, will be critical if we are to seize the promise for science and tech innovations to support the government’s missions to grow the economy, fix the National Health Service (NHS) and improve health outcomes and deliver clean energy under the Plan for Change. As the Plan sets out, promoting innovation and world-class research will be foundational to rebuilding the foundations of the economy, and kickstarting growth.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More on this story...

Pharmaceutical
UK outlines vision for Horizon Europe successor
26 September 2024
Pharmaceutical
Getting the most out of AI foundation models: tips for pharmaceutical companies
4 July 2024


More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news

Today's issue

Delay for Biohaven’s troriluzole NDA
Pharmaceutical
Delay for Biohaven’s troriluzole NDA
16 May 2025
Biotechnology
Incyte granted FDA approval of Zynyz for SCAC
16 May 2025
Biotechnology
Gene therapy’s worth for eye disease assessed
16 May 2025
Pharmaceutical
METiS Pharmaceuticals eyes $200 million IPO
16 May 2025
Biotechnology
ICON holds lead as most active CRO, GlobalData finds
16 May 2025
Pharmaceutical
Neurocrine reports progress for CAH drug as Voyager partnership shifts
16 May 2025
Biotechnology
Pathos AI lands $365 million for AI-driven cancer drugs
16 May 2025

Company Spotlight

Inozyme Pharma is a biotechnology company developing new medicines to treat rare disorders of calcification.




More Features in Pharmaceutical

Delay for Biohaven’s troriluzole NDA
16 May 2025
METiS Pharmaceuticals eyes $200 million IPO
16 May 2025
Neurocrine reports progress for CAH drug as Voyager partnership shifts
16 May 2025
Travere flops as FDA accepts Filspari sNDA but plans AdCom
16 May 2025


The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze